甲状腺未分化癌的免疫治疗:曙光初现,未来可期

Immunotherapy: a promising therapy for anaplastic thyroid carcinoma

甲状腺未分化癌(anaplastic thyroid carcinoma,ATC)是一种罕见但恶性程度极高的肿瘤,目前还没有有效的治疗方法。ATC的免疫微环境研究提示,免疫治疗可能使ATC患者获益。已有一些免疫治疗ATC的相关研究陆续开展。免疫检查点抑制剂(单独或与靶向药物联用)、嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)免疫疗法和个性化肿瘤疫苗(personalized tumor vaccines,PTV)等有望成为ATC治疗的未来方向。

Anaplastic thyroid carcinoma(ATC)is rare but one of the most aggressive human cancers,and there is no effective treatments currently. Studies of immune microenvironment in ATC suggest that immunotherapy may benefit for ATC patients,and some studies about immunotherapy in ATC have been gradually conducted. Immune checkpoint inhibitors(given alone or combined with target agents),chimeric antigen receptor T cell(CAR-T),and personalized tumor vaccines(PTV)were expected to be the future direction of medical therapy for ATC.